NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-22-002 from the NIH Guide for Grants and Contracts
Notice NOT-HL-21-026 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-003 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-038 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-941. The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates)are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs.
Funding Opportunity PAR-22-039 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-942. The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not withinthe scope of this announcement.
Funding Opportunity PAR-21-341 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, health care delivery or clinical).
Notice NOT-HD-21-044 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-001 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-004 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-040 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows in the NHLBI Division of Intramural Research the opportunity to transition their research programs as new investigators to extramural institutions. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution.
Funding Opportunity PAR-22-034 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows and other doctoral-level researchers still in training in the NHLBI Division of Intramural Research the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing to serve as lead investigator of a clinical trial or an ancillary study to an ongoing clinical trial, should apply to the companion FOA, PAR-22-040 "NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22- Clinical Trial Required).
Notice NOT-TR-22-002 from the NIH Guide for Grants and Contracts
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
Funding Opportunity PAR-21-321 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.
Funding Opportunity RFA-MH-22-120 from the NIH Guide for Grants and Contracts. To address increasing US suicide rates, NIMH, as a federal partner of the National Action Alliance for Suicide Prevention, seeks to reduce suicide by building evidence-based suicide prevention in healthcare systems. Improving suicide prevention in primary care is essential to overall healthcare system safe suicide care capabilities. The American Medical Association and the American Academy of Pediatricians, for example, have indicated to NIMH that many primary care providers are willing to identify patients at risk via screening, but are uncertain about optimal ways to perform assessments, brief interventions, and appropriate referrals. In addition to identifying risk in patients, primary care providers often see patients for follow-up after ED or inpatient care visits, and they seek to be better equipped to address patient safety needs to prevent relapse.
Funding Opportunity RFA-NS-22-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to accelerate development, testing and implementation of evidence-based interventionsthat are culturally and linguistically appropriate for NIH-designated health disparity populations[1] (HDPs)to mitigate disparities in provision of care and treatment decisions, reduce susceptibility to chronic pain and improve patient outcomes. Applications are encouraged for studies that utilize evidence-based strategies that mitigate: 1) the effects of bias, stigma and discrimination at multiple levels, and 2) socioeconomic, environmental and other barriers to quality pain assessment, treatment and management are desired outcomes of this initiative. Strategies to increase successful HDP patient engagement and bolster inclusion to enhance better pain management outcomes are also desired.
Funding Opportunity RFA-GM-22-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide opportunities for eligible U.S. small business concerns (SBCs), together with academic partners, in each of the four regions of the Institutional Development Award (IDeA)-eligible states, to apply forIDeA Regional Entrepreneurship Development (I-RED) program awards that support the development of educational products to promote biomedical entrepreneurship in IDeA states. These educational products are expected to address the needs of IDeA state academic institutions in developing and/or strengthening technology transfer programs that stimulate technological innovation and the needs of IDeA state investigators in translating scientific discoveries and technologies from research laboratories into commercial products that improve human health and promote economic growth in IDeA states.
Notice NOT-DE-21-013 from the NIH Guide for Grants and Contracts
Notice NOT-DK-22-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-22-025 from the NIH Guide for Grants and Contracts. The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a clinical trial but are not required to (optional).
Funding Opportunity RFA-RM-21-024 from the NIH Guide for Grants and Contracts. This U41 opportunity will fund Centers to create interoperable open-source modules that can be combined into custom profiles for new exploratory and clinical neuromodulation studies in the peripheral nervous system, and for potential applicability in the central nervous system. The centers will disseminate the open-source neuromodulation resources broadly.